ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,064.20
0.91%
Dow Jones
38,225.66
0.85%
US Dollar vs MXN
16.9587
-0.08%
Brent Oil
83.555
-0.09%
Bitcoin
59,409.46
0.49%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Vaxart Inc (VXRT)

  7. Vaxart Inc (VXRT) Noticias

VXRT Vaxart Inc

0.749
0.00 (0.00%)
Pre Mercado
Última actualización: 03:00:00
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Vaxart Inc VXRT NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.00 0.00% 0.749 03:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.749
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
30/4/202407:00GLOBEVaxart Announces Positive Results for Its Bivalent Norovirus..
27/3/202407:00GLOBEVaxart to Present at World Vaccine Congress Washington 2024..
20/3/202407:00GLOBEVaxart, Inc. Reports Inducement Grants Under Nasdaq Listing..
14/3/202415:01GLOBEVaxart Provides Business Update and Reports Full Year 2023..
14/3/202406:41IHMARKETNEWSU.S. Stock Futures Rise Ahead Of PPI and Retail Sales; Oil..
07/3/202407:00GLOBEVaxart to Host Full Year 2023 Business Update and Financial..
06/3/202408:23EDGAR2Form 8-K - Current report
06/3/202407:00GLOBEVaxart, Inc. Appoints Steven Lo as President, Chief..
29/2/202415:30EDGAR2Form 8-K - Current report
15/2/202415:10EDGAR2Form 8-K - Current report
13/2/202416:16EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
05/2/202407:00GLOBEVaxart Announces Publication in Vaccines of Non-Human..
02/2/202415:49EDGAR2Form 8-K/A - Current report: [Amend]
19/1/202416:14EDGAR2Form 8-K - Current report
19/1/202415:30EDGAR2Form SC 13G - Statement of acquisition of beneficial..
19/1/202407:30GLOBEVaxart Receives $9.27 Million BARDA Project NextGen Award to..
16/1/202416:18EDGAR2Form 8-K - Current report
16/1/202408:25GLOBEVaxart Announces $10.0 Million Registered Direct Offering..
16/1/202408:22GLOBEVaxart, Inc. Announces Management Change
16/1/202408:19EDGAR2Form 8-K - Current report
21/12/202307:00GLOBEVaxart Announces Last Subject Dosed in Phase 1 Trial of Its..
02/11/202315:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202315:11EDGAR2Form 8-K - Current report
02/11/202315:01GLOBEVaxart Provides Business Update and Reports Third Quarter..
02/11/202307:00GLOBEVaxart Doses First Subject in Phase 1 Trial of Its Norovirus..
26/10/202307:00GLOBEVaxart to Host Third Quarter 2023 Business Update and..
23/10/202316:09EDGAR2Form 8-K/A - Current report: [Amend]
23/10/202316:01EDGAR2Form 8-K - Current report
11/10/202307:00GLOBEVaxart to Present at World Vaccine Congress Europe 2023 on..
21/9/202307:00GLOBEVaxart to Participate in Fireside Chat at 2023 Cantor Global..
06/9/202315:43EDGAR2Form 8-K - Current report
06/9/202315:05GLOBEVaxart Announces Topline Data from the Phase 2 Challenge..
03/8/202315:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/8/202315:20EDGAR2Form 8-K - Current report
03/8/202315:01GLOBEVaxart Provides Business Update and Reports Second Quarter..
01/8/202320:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/8/202320:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/8/202320:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/8/202320:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/8/202319:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/7/202307:00GLOBEVaxart to Host Second Quarter 2023 Business Update and..
26/7/202315:20EDGAR2Form 8-K - Current report
10/7/202315:12EDGAR2Form 8-K - Current report
06/7/202307:00GLOBEVaxart Announces Positive Preliminary Topline Data from..
28/6/202315:22EDGAR2Form 8-K - Current report
26/6/202315:45GLOBEVaxart Stockholders Approve All Four Proposals in the 2023..
21/6/202315:30GLOBEVaxart Encourages All Stockholders of Record as of April 28,..
07/6/202308:16GLOBEVaxart, Inc. Announces Pricing of $15,000,000 Public..
06/6/202315:01GLOBEVaxart, Inc. Announces Proposed Public Offering of Common..
06/6/202307:00GLOBEVaxart Announces Last Subject Dosed in Phase 2 Trial of its..

Su Consulta Reciente

NASDAQ
VXRT
Vaxart
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados